BioVie Inc (NASDAQ:BIVI) will present blinded data from a Phase 3 clinical trial for NE3107 in Alzheimer's Disease at the 16th CTAD in Boston. The presentation will provide insights into the trial's cognitive, biomarker, and imaging findings. The data will be unveiled during an oral presentation on October 25, 2023, and further details will be shared once made public at the conference.
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com